Breaking News Instant updates and real-time market news.

GOOG

Alphabet

$768.79

22.88 (3.07%)

, GOOGL

Alphabet Class A

$791.34

25.5 (3.33%)

16:35
07/29/16
07/29
16:35
07/29/16
16:35

On The Fly: Top stock stories for Friday

Stocks began the day mixed and remained that way throughout the session. Investors were inundated with data from both corporate earnings and economic reports and while they spent the day sifting through it, the market drifted. Oil prices remained under pressure but rallied late in the day to close higher. Despite today's small bounce back, the price of U.S. West Texas Intermediate crude ended the month of July about 15% lower and hovering near $41 per barrel. ECONOMIC EVENTS: In the U.S., gross domestic product grew at only a seasonally adjusted annual rate of 1.2% in the second quarter, well below the 2.6% growth economists had forecast. The Chicago PMI Business Barometer Index came in at 55.8, better than the 54.0 reading expected. The University of Michigan's consumer sentiment survey fell to 90.0 in the final read for July, down from June's 93.5 reading. Baker Hughes reported that the U.S. rig count was up 1 rig from last week to 463 rigs, keeping up a recent trend of rig additions. In Asia, the Bank of Japan said it would double its ETF asset purchase target to Y6T from Y3.3T but left unchanged its other policy tools, including the monetary base target and the deposit rate. COMPANY NEWS: Class A shares of Alphabet (GOOGL) advanced 3.33% to $791.34 after Google's parent company announced better-than-expected second quarter results, which sparked several price target hikes from Wall Street analysts. Similarly, Amazon (AMZN) shares rose 0.82% to $758.81 after the e-commerce and cloud giant posted its third consecutive record profit... Earnings at Exxon Mobil (XOM) missed expectations, sending the stock down 1.39% to $88.95. For the weak results, the oil major blamed sharply lower commodity prices, weaker refining margins and the "volatile industry environment." Chevron (CVX), which surprised with a quarterly loss due to $2.8B in impairments and charges on assets where revenue from expected production is expected to be insufficient to recover costs, managed to finish with a small gain of 0.68%, closing at $102.48... Merck (MRK) reported better than expected quarterly profits and raised the bottom end of its full-year earnings range, while pharmaceutical industry peer AbbVie (ABBV) posted better than expected sales and profits and raised its fiscal year outlook. MAJOR MOVERS: Among the notable gainers was Newell Brands (NWL), which gained 6.22% after reporting quarterly results. Additionally, Molson Coors (TAP) rose about 4.5% after SABMiller's (SBMRY) board announced it intends to recommend unanimously the revised and final offer announced by Anheuser-Busch InBev (BUD). As part of the brewing giants' deal, Molson Coors will acquire SABMiller's stake in their MillerCoors joint venture. Among the noteworthy losers was Seres Therapeutics (MCRB), which plunged 2.04% after the company announced a clinical study of SER-109 for the prevention of multiply recurrent C.difficile infection did not achieve its primary endpoint. Also lower was Stericycle (SRCL), which slipped 14.78% after the company reported inline results, but gave an earnings outlook that was well below consensus. Also falling after their quarterly reports were Western Digital (WDC) and Cigna (CI), which dropped 11.53% and 5.13%, respectively. INDEXES: The Dow fell 24.11, or 0.13%, to 18,432.24, the Nasdaq gained 7.15, or 0.14%, to 5,162.13, and the S&P 500 added 3.54, or 0.16%, to 2,173.60.

GOOG

Alphabet

$768.79

22.88 (3.07%)

GOOGL

Alphabet Class A

$791.34

25.5 (3.33%)

AMZN

Amazon.com

$759.21

6.6 (0.88%)

XOM

Exxon Mobil

$88.95

-1.25 (-1.39%)

CVX

Chevron

$102.48

0.69 (0.68%)

MRK

Merck

$58.66

0.23 (0.39%)

ABBV

AbbVie

$66.23

1.51 (2.33%)

NWL

Newell Brands

$52.46

3.07 (6.22%)

TAP

Molson Coors

$102.16

4.41 (4.51%)

BUD

AB InBev

$129.44

3.52 (2.80%)

SBMRY

SABMiller

$58.69

1.135 (1.97%)

MCRB

Seres Therapeutics

$10.94

-24.83 (-69.42%)

SRCL

Stericycle

$90.27

-15.66 (-14.78%)

WDC

Western Digital

$47.51

-6.19 (-11.53%)

CI

Cigna

$128.96

-7.03 (-5.17%)

  • 29

    Jul

  • 29

    Jul

  • 29

    Jul

  • 29

    Jul

  • 29

    Jul

  • 29

    Jul

  • 29

    Jul

  • 29

    Jul

  • 02

    Aug

  • 08

    Sep

  • 13

    Sep

  • 16

    Oct

  • 23

    Oct

  • 02

    Nov

GOOG Alphabet
$768.79

22.88 (3.07%)

07/29/16
JEFF
07/29/16
NO CHANGE
Target $1000
JEFF
Buy
Alphabet price target raised to $1,000 from $925 at Jefferies
Jefferies analyst Brian Pitz raised his price target for Alphabet to $1,000 saying the company's Q2 beat reflects accelerating growth at Google Websites, namely mobile search and YouTube. The analyst continues to believe that online video is the biggest online ad growth driver and YouTube is the premier vehicle to play that trend. He reiterates a Buy rating on Alphabet. The shares are up 4% to $798.60 in pre-market trading.
07/29/16
OPCO
07/29/16
NO CHANGE
Target $970
OPCO
Outperform
Alphabet price target raised to $970 from $958 at Oppenheimer
Oppenheimer analyst Jason Helfstein raised his price target for Alphabet (GOOG) to $970 from $958 following "strong" Q2 results. The analyst says concerns of share loss to Facebook (FB) seem unfounded, and notes that Alphabet continues to gain share from traditional media/legacy display. He reiterates an Outperform rating on Alphabet's shares.
07/29/16
JPMS
07/29/16
NO CHANGE
Target $950
JPMS
Overweight
Alphabet price target raised to $950 from $920 at JPMorgan
JPMorgan analyst Doug Anmuth raised his price target for Alphabet to $950 saying the company's revenue growth accelerated in Q2. The analyst reiterates an Overweight rating on the shares.
07/29/16
NEED
07/29/16
NO CHANGE
Target $900
NEED
Buy
Alphabet price target raised to $900 from $825 at Needham
Needham analyst Kerry Rice raised his price target for Alphabet to $900 from $825 after the company delivered "strong" Q2 upside highlighted by accelerating Google Website's growth and rising operating margin year over year in its Google segment. Mobile search was the key growth driver in Q2 with YouTube and programmatic supplementing the "strong" growth, the analyst tells investors in a research note. Needham has a Buy rating on the shares.
GOOGL Alphabet Class A
$791.34

25.5 (3.33%)

07/29/16
07/29/16
NO CHANGE

Alphabet 'hit a home run,' says Pacific Crest
Pacific Crest analyst Evan Wilson says that Alphabet exceeded Q2 expectations by a large amount. The analyst says he's still "excited" about the company's revenue growth, expense control and cash return levels. He raised his price target on the shares to $960 from $910 and recommends buying the stock.
AMZN Amazon.com
$759.21

6.6 (0.88%)

07/29/16
OPCO
07/29/16
NO CHANGE
Target $941
OPCO
Outperform
Amazon.com price target raised to $941 from $930 at Oppenheimer
Oppenheimer analyst Jason Helfstein raised his price target for Amazon.com to $941 from $930 following "exceptional" Q2 results on revenue and margins. The analyst says Amazon.com is one of the few large-cap companies benefiting from the secular shift to eCommerce, continuing to gain share of U.S. eCommerce with its deep product selection, low-cost express delivery through its Prime program, and breakthrough success of Kindle and other emerging media content. Helfstein reiterates an Outperform rating on the shares.
07/29/16
BMOC
07/29/16
NO CHANGE
BMOC
Amazon investments to limit Q3 profit, says BMO Capital
BMO Capital analyst Daniel Salmon says that Amazon's Q3 operating profit guidance came in below expectations largely because of investments that the company is making in capacity for the holiday season and in content for its digital offering. The analyst thinks that the company's consolidated margins will increase going forward, and he says that AWS posted strong results. Salmon raised his price target on the shares to $875 from $800 and keeps an Outperform rating on the stock.
07/29/16
NEED
07/29/16
NO CHANGE
NEED
Hold
Needham remains cautious on Amazon.com given accelerating investments
Following Amazon's quarterly results, Needham analyst Kerry Rice says he expects gross margin to expand, but heavy investment in content and infrastructure in the second half of 2016 may moderate consolidated segment operating income, or CSOI, growth. While Rice is encouraged by the accelerating revenue growth and higher levels of operating income, he remains "somewhat cautious" on Amazon.com given the expectations for accelerated investment in the second half of the year. Needham has a Hold rating on the shares.
07/29/16
RBCM
07/29/16
NO CHANGE
RBCM
Amazon.com price target raised to $840 from $800 at RBC Capital
After Amazon reported better than expected results, RBC Capital analyst Mark Mahaney says that investors were concerned about the company's lower than expected Q3 operating income guidance. The analyst notes that the company's retail growth accelerated, while AWS outperformed last quarter. Moreover,, Mahaney expects Amazon's revenue growth to remain strong while its margins continue to rise going forward. He keeps an Outperform rating on the shares.
XOM Exxon Mobil
$88.95

-1.25 (-1.39%)

06/02/16
06/02/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Exxon Mobil (XOM) downgraded to Neutral from Buy at BofA/Merrill with analysts led by Doug Leggate saying Exxon's strong relative performance discount's long-term oil at around $73/bbl and said shares appear to be fairly valued. 2. Intuitive Surgical (ISRG) downgraded to Neutral from Buy at Goldman with analyst David Roman saying the risk/reward looks balanced at current share levels. Roman lowered his price target for the stock to $674 from $690. 3. DeVry (DV) downgraded to Neutral from Outperform at Credit Suisse with analyst Trace Urdan saying he no longer feels confident in his investment thesis following the resignation of CFO Tim Wiggins. 4. Franklin Resources (BEN) downgraded to Sell from Neutral at UBS with analyst Brennan Hawken arguing the company is the most exposed to the Department of Labor's fiduciary rule of the names he covers given its reliance on the broker sold channel coupled with weak investment performance. He cut his price target for the shares to $28 from $39. 5. Progressive (PGR) downgraded to Sell from Neutral at Citi with analyst James Naklicki saying consensus margin and earnings expectations are too optimistic. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/02/16
06/02/16
DOWNGRADE

Neutral
Exxon Mobil downgraded to Neutral on valuation at BofA/Merrill
As previously reported, BofA/Merrill downgraded Exxon Mobil to Neutral from Buy. Analysts led by Doug Leggate said Exxon's strong relative performance discount's long-term oil at around $73/bbl and said shares appear to be fairly valued.
07/05/16
FBCO
07/05/16
NO CHANGE
FBCO
Outperform
Fluor scope on 'imminent' project could be multiple billions, says Credit Suisse
Credit Suisse Jamie Cook noted that the Tengizchevron joint venture, which is 50% owned by Chevron (CVX), 25% by ExxonMobil (XOM), 20% owned by KazMunayGas, and 5% owned by Lukoil, has announced plans to move forward with the TCO project, adding that Fluor (FLR) has been doing extensive work on TCO with its JV partner WorleyParsons and that most investors believed the likelihood of this project moving forward was "minimal." Cook, who believes Fluor's scope on this project could be "north of a couple billion" and that the company could book this award in Q2 or Q3 of this year, has an Outperform rating on Fluor shares.
06/02/16
BOFA
06/02/16
DOWNGRADE
BOFA
Neutral
Exxon Mobil downgraded to Neutral from Buy at BofA/Merrill
CVX Chevron
$102.48

0.69 (0.68%)

04/04/16
JEFF
04/04/16
NO CHANGE
Target $110
JEFF
Buy
Jefferies says Chevron still top pick in Integrated Oil
Jefferies analyst Jason Gammel says Chevron his firm's top pick in the Integrated Oil sector. The company is positioned to generate the highest organic production growth in the space and its free cash flow generation should "improve significantly" through 2018, Gammel tells investors in a research note. He believes Chevron can fund its dividend with free cash flow with a Brent oil price as low as $50 per barrel. The analyst keeps a Buy rating on the stock with a $110 price target.
05/17/16
ARGS
05/17/16
NO CHANGE
ARGS
Chevron price target raised to $118 from $100 at Argus
Argus raised its price target on Chevron citing the increase in crude oil prices and its belief that the company's dividend is secure. The firm says that the company's cash flow should be boosted by its recently completed projects. Argus keeps a Buy rating on the shares.
04/13/16
LYON
04/13/16
NO CHANGE
LYON
Russian oil minister sees 'loosely-framed' oil output deal, Reuters reports
Russian oil minister Alexander Novak said he expects the upcoming oil output freeze deal to be signed by some of world's top oil producers when they meet in Doha to be "loosely-framed with few detailed commitments," according to Reuters, citing sources recounting Novak's comments during a closed-door briefing. Publicly traded oil majors include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT). Reference Link
MRK Merck
$58.66

0.23 (0.39%)

07/14/16
JEFF
07/14/16
NO CHANGE
JEFF
AbbVie remains Jefferies' Top Pick in Global Pharma
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his firm's Top Pick in Global Pharmaceuticals, followed by Eli Lilly (LLY), Novartis (NVS), GlaxoSmithKline (GSK) and Zoetis (ZTS). The analyst this morning upgraded GSK to Buy from Hold. Holford also remains positive on Roche (RHHBY), Abbott (ABT) and Pfizer (PFE). The analyst's least preferred names are Novo Nordisk (NVO), Johnson & Johnson (JNJ) and Merck (MRK). The Q2 earnings season offers "few clear beat and raise" stories and looks weakest for AstraZeneca (AZN) against preliminary consensus, Holford tells investors in a pre-earnings research note.
07/18/16
BMOC
07/18/16
DOWNGRADE
BMOC
Market Perform
Merck downgraded to Market Perform from Outperform at BMO Capital
07/18/16
07/18/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. 3D Systems (DDD) downgraded to Underweight from Neutral and Stratasys (SSYS) downgraded to Neutral from Overweight at Piper Jaffray with analyst Troy Jensen saying his channel checks and quarterly 3D printing survey indicated the industry experienced a "significant slowdown in system demand" in the June quarter. 2. Infosys (INFY) downgraded to Neutral from Outperform at Credit Suisse and to Neutral from Buy at Nomura. Credit Suisse analyst Anantha Narayan downgraded Infosys citing a lack of near-term catalysts for shares to move higher amid the company's slowing growth. 3. KB Home (KBH) downgraded to Neutral from Buy at Buckingham with the firm citing moderating 2017 earnings growth, leverage and inconsistent execution, and recent share strength. 4. CONSOL (CNX) and Devon Energy (DVN) downgraded to Accumulate from Buy at KLR Group with analyst John Gerdes citing valuation. 5. Merck (MRK) downgraded to Market Perform from Outperform at BMO Capital with the firm citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/18/16
BMOC
07/18/16
DOWNGRADE
BMOC
Market Perform
Merck downgraded on valuation at BMO Capital
As noted earlier, BMO Capital downgraded Merck to Market Perform from Outperform. The firm downgraded the stock based on valuation. Target $62.
ABBV AbbVie
$66.23

1.51 (2.33%)

07/01/16
MZHO
07/01/16
NO CHANGE
Target $8
MZHO
Buy
OraSure, AbbVie HVC agreement termination not a negative, says Mizuho
Mizuho analyst Eric Criscuolo believes the termination of OraSure's (OSUR) HCV co-promotion agreement with AbbVie (ABBV) is less a negative than may appear. The analyst does not forecast a negative impact to product sales, and sees the $12M per year in exclusivity revenue from 2017-2019 that goes away as the biggest downside since the deal never had the positive impact that was expected. Furthermore, expenses will fall and OraSure's HCV control will increase, Criscuolo tells investors in a research note, adding that a "potentially lucrative" international HCV contract and additional molecular customers make him positive on growth drivers. He reiterates a Buy rating and $8 price target on OraSure's shares.
06/15/16
RBCM
06/15/16
DOWNGRADE
RBCM
Sector Perform
Infinity Pharmaceuticals downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Infinity (INFI) after the company announced a restructuring and said it hoped duvelisib as a monotherapy would have provided a larger clinical benefit for patients with advanced indolent non-Hodgkin lymphoma. The firm says it's unclear if the FDA will accept a filing by Infinity, while it's also unclear if AbbVie (ABBV) will continue its partnership with the company. Target to $2 from $12.
06/16/16
LEER
06/16/16
NO CHANGE
Target $104
LEER
Outperform
Vertex remains ahead in cystic fibrosis, says Leerink
During their Annual R&D Update, Leerink analyst Geoffrey Porges says Galapagos (GLPG) presented the development plans for its cystic fibrosis franchise, in partnership with AbbVie (ABBV), which is a current threat to Vertex (VRTX). The announcement represents an "aggressive timeline" that would allow for a pivotal phase 3 for Galapagos' triple combination to begin in 2018 as a best case scenario, Porges tells investors in a research note. Nonetheless, the analyst believes Vertex's next generation combinations are much further along in development, with the company currently having a number of dual combination phase 3 trials underway. Porges reiterates an Outperform rating and $104 price target on Vertex's shares.
NWL Newell Brands
$52.46

3.07 (6.22%)

05/19/16
RBCM
05/19/16
NO CHANGE
RBCM
Newell Brands new CFO has several positive attributes, says RBC Capital
RBc Capital believes that Newell's (NWL) new CFO, Ralph Nicoletti, will bring "increased financial discipline," a focus on total shareholder returns, "and a very analytical, research driven approach to decision making and strategy" to the position. The firm notes that some investors have been concerned about the 36% underperformance by Tiffany's (TIF) stock during his tenrue at that company. However, RBC says that Tiffany's results have always been "volatile," particularly recently due to macro issues. RBC says that the shares of Alberto-Culver and Cigna (CI) outperformed during Nicoletti's stints as CFO of those companies. RBC keeps a $60 price target and Top Pick rating on Newell.
04/08/16
JEFF
04/08/16
NO CHANGE
Target $51
JEFF
Buy
Newell Rubbermaid offers 'very good value' at these levels, says Jefferies
After hosting the company's NWL's VP of Investor Relations, Nancy O'Donnell, Jefferies analyst Kevin Grundy says shares of Newell Rubbermaid offer "very good value here for investors." The analyst continues to see a path to $73 per share over the next two-to-three years. Grundy views Newell as a top pick and keeps a Buy rating on the name with a $51 price target.
04/18/16
MSCO
04/18/16
NO CHANGE
Target $55
MSCO
Overweight
Newell Brands valuation does not reflect earnings potential, says Morgan Stanley
Morgan Stanley analysts led by Dara Mohsenian said Newell Brands' valuation does not accurately reflect strong growth potential and earnings upside following the Jardan acquisition. The analyst said overblown bear concerns have dragged down Newell's valuation and she is confident in management's ability to drive shareholder value over the next few years. Mohsenian reiterates her Overweight rating and Newell as a top HPC Pick.
05/09/16
JEFF
05/09/16
NO CHANGE
Target $59
JEFF
Buy
Newell Brands price target raised to $59 from $53 at Jefferies
Jefferies analyst Kevin Grundy raised his price target for Newell Brands to $59 saying the company's Q1 results were good and its outlook for FY16 is even better. The stock remains a top pick of Grundy's.
TAP Molson Coors
$102.16

4.41 (4.51%)

07/29/16
SBSH
07/29/16
UPGRADE
Target $115
SBSH
Buy
Molson Coors upgraded to Buy from Neutral at Citi
Citi analyst Wendy Nicholson upgraded Molson Coors (TAP) to Buy citing the recent pullback in the shares. The analyst is optimistic that both the AB InBev (BUD)/SABMiller (SBMRY) and Molson Coors/MillerCoors transactions will close in early Fall 2016. Nicholson raised her price target for the shares to $115 from $101.
07/29/16
07/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dow Chemical (DOW) upgraded to Overweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying global demand is "holding up generally well" following the company's second quarter results. 2. Molson Coors (TAP) upgraded to Buy from Neutral at Citi with analyst Wendy Nicholson citing the recent pullback in the shares. 3. Oshkosh (OSK) upgraded to Outperform from Sector Perform at RBC Capital with analyst Seth Weber saying he believes that the outlook for the company's Acess equipment and defense units has improved. 4. Pinnacle Foods (PF) upgraded to Buy from Hold at Stifel. 5. Western Digital (WDC) upgraded to Outperform from Neutral at Baird. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/04/16
STFL
05/04/16
NO CHANGE
STFL
Molson Coors 'underlying outlook improving,' says Stifel
After Molson Coors reported stronger than expected Q1 results, Stifel says that the company's "underlying outlook is improving," particularly in Europe and the U.S. The firm raised its price target on the name to $119 from $115 and keeps a Buy rating on the shares.
06/07/16
SUSQ
06/07/16
NO CHANGE
Target $130
SUSQ
Positive
Molson Coors investor day unlikely to move stock, says Susquehanna
Susquehanna noted the recent outperformance of Molson Coors shares and said they do not believe the company's upcoming investor day will move the shares. The firm feels better catalysts would be cost savings opportunities, plans to improve the brand portfolio, and more quantifiable explanations for the profit margin gap up for MillerCoors. Susquehanna reiterated its Positive rating and $130 price target on Molson Coors shares.
BUD AB InBev
$129.44

3.52 (2.80%)

07/28/16
07/28/16
DOWNGRADE

AB InBev downgraded to Hold from Add at Bank Degroof Petercam
07/13/16
ROTH
07/13/16
NO CHANGE
Target $15
ROTH
Buy
Roth Capital remains a buyer of Craft Brew amid takeover speculation
Roth Capital analyst Anton Brenner says Craft Brew Alliance's (BREW) shares have appreciated sharply recently, largely on speculation of an acquisition of the company, or of the fast-growing Kona brand, fueled by Anheuser-Busch Inbev's (BUD) 32% ownership of Craft Brew. The analyst notes that such a transaction suggests "significant upside potential." Nonetheless, he reiterates a Buy rating on Craft Brew's shares with a $15 price target primarily on the expectation of an acceleration in volume growth and profit margin expansion over the next three years.
07/19/16
STFL
07/19/16
NO CHANGE
STFL
SABMiller deal could be blocked, terms may be sweetened says Stifel
Stifel believes that a minority SABMiller (SBMRY) shareholders could "effectively block" the company's proposed acquisition by AB InBev (BUD). The firm thinks that the deal's small premium and "the illiquidity" of AB's stock that would be transferred in the alternative, partial stock offering could motivate SABMiller's shareholders to block the deal. The firm thinks that AB InBev could sweeten the terms of the deal.
SBMRY SABMiller
$58.69

1.135 (1.97%)

03/22/16
03/22/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. EP Energy (EPE) downgraded to Underperform and Underweight at BofA/Merrill and Capital One, respectively, with analysts saying EP Energy's planned sale of Haynesville for $420mm is not a surprise and balance sheet headwinds remain. BofA/Merrill continues to see leverage as a headwind and does not see how the company can live within its cash flow while production declines in 2016. 2. Amazon.com (AMZN) downgraded to Outperform at Raymond James by analyst Aaron Kessler, who expects Amazon's pace of margin expansion to slow and he sees increased competition to its Web Services unit from Google's (GOOG, GOOGL) Cloud Platform. 3. Copa Holdings (CPA) downgraded to Sell at Evercore ISI by analyst Duane Pfennigwerth, who cited recent shares strength. 4. Infinity Pharmaceuticals (INFI) downgraded to Underperform from Neutral at Wedbush. 5. SABMiller (SBMRY) downgraded to Underperform at CLSA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/22/16
LYON
03/22/16
DOWNGRADE
LYON
Underperform
SABMiller downgraded to Underperform from Outperform at CLSA
MCRB Seres Therapeutics
$10.94

-24.83 (-69.42%)

03/30/16
03/30/16
INITIATION
Target $40

Outperform
Seres Therapeutics initiated with an Outperform at FBR Capital
FBR Capital analyst Vernon Bernardino started Seres Therapeutics with an Outperform rating and $40 price target.
07/29/16
HCWC
07/29/16
INITIATION
Target $50
HCWC
Buy
Seres Therapeutics assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther resumed coverage of Seres Therapeutics with a Buy rating and $50 price target.
06/06/16
COWN
06/06/16
INITIATION
COWN
Outperform
Seres Therapeutics initiated with an Outperform at Cowen
Cowen analyst Ritu Baral initiated Seres Therapeutics with an Outperform citing high confidence of success in the very near-term Phase II data of lead microbiome candidate SER-109 in prevention of multiply recurrent C. Diff infection. He also sees meaningful value in MCRB's platform and pipeline including Ph2-ready SER-262 for prevention of primary CDI recurrence and Ph1/2 SER-287 in ulcerative colitis.
03/03/16
GUGG
03/03/16
INITIATION
Target $41
GUGG
Buy
Seres Therapeutics initiated with a Buy at Guggenheim
Target $41.
SRCL Stericycle
$90.27

-15.66 (-14.78%)

07/29/16
IMPC
07/29/16
DOWNGRADE
IMPC
Underperform
Stericycle downgraded to Underperform from In-Line at Imperial Capital
Imperial Capital analyst Scott Levine downgraded Stericycle to Underperform and lowered his price target for the shares to $93.50 from $100. The analyst wants to see a reacceleration in earnings growth and improvement in its visibility before getting more positive.
05/16/16
STFL
05/16/16
NO CHANGE
STFL
Takeover of Stericycle could be 'compelling' for Waste Management, says Stifel
Stifel believes that an acquisition of Stericycle (SRCL) could be "compelling" for Waste Management (WM) if the deal could be done at 10.6 times. The firm notes that Stericycle's sales are growing at a "mid to upper digit" rate, versus 2%-3% growth at Waste Management. The firm keeps a Buy rating on Waste Management and a Hold rating on Stericycle.
07/29/16
WLSD
07/29/16
DOWNGRADE
WLSD
Hold
Stericycle downgraded to Hold from Gradually Accumulate at Wellington Shields
07/18/16
JEFF
07/18/16
NO CHANGE
Target $140
JEFF
Buy
Stericycle risk/reward attractive into Q2 results, says Jefferies
Jefferies analyst Sean Dodge views the risk/reward for shares of Stericycle as attractive into the company's Q2 results. The analyst believes an in-line quarter will take the stock higher. He has a Buy rating on the name with a $140 price target.
WDC Western Digital
$47.51

-6.19 (-11.53%)

07/29/16
BMUR
07/29/16
NO CHANGE
Target $97
BMUR
Buy
Western Digital pullbacks would be buying opportunity, says Brean Capital
Brean Capital said they would absolutely be buying any pullbacks in Western Digital shares following Q4 earnings. The firm noted shares were down after its report and were confused as they expected shares to trade higher. Brean Capital views company guidance as conservative and favorable considering investors were concerned about guidance. Brean Capital reiterated its Buy rating and $97 price target on Western Digital shares.
07/29/16
07/29/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. GrubHub (GRUB) downgraded to Neutral from Buy at BofA/Merrill, to Neutral from Buy at Monness Crespi, and to Hold from Buy at Maxim. 2. Ford (F) downgraded to Neutral from Buy at Goldman with analyst Patrick Archambault saying share outperformance over the next 6-12 months will be difficult following the carmaker's weaker than expected second quarter results and profit warning for 2016. 3. Starz (STRZA) downgraded to Hold from Buy at Pivotal Research with analyst Jeffrey Wlodarczak saying the Starz/Lionsgate (LGF) pro-forma entity is fairly valued. 4. Western Digital (WDC) downgraded to Hold from Buy at Cross Research with the firm saying the company is either unwilling or unable to provide a reasonable level of precision to the newly combined businesses with SanDisk and the higher than expected cost structure, combined with compensation increases will be a drag. 5. Wynn Resorts (WYNN) downgraded to Reduce from Neutral at Nomura and to Underperform from Outperform at CLSA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/29/16
CRSS
07/29/16
DOWNGRADE
CRSS
Hold
Western Digital downgraded to Hold from Buy at Cross Research
Cross Research downgraded Western Digigal to Hold saying the company is either unwilling or unable to provide a reasonable level of precision to the newly combined businesses with SanDisk and the higher than expected cost structure, combined with compensation increases will be a drag.
CI Cigna
$128.96

-7.03 (-5.17%)

07/29/16
STFL
07/29/16
NO CHANGE
STFL
Buy
Cigna weakness a buying opportunity, say Stifel
07/22/16
COWN
07/22/16
NO CHANGE
Target $160
COWN
Outperform
Cigna has greatest upside should DOJ block mergers, says Cowen
Cowen noted the DOJ tone toward the pending managed care deals is decidedly negative and raised the burden of proof on the companies to demonstrate the deals are not anti-competitive. Cowen believes Cigna has the most upside of the four companies involved whether the deals go through or not. Cowen has an Outperform rating and $160 price target on Cigna shares.
07/22/16
GSCO
07/22/16
UPGRADE
Target $165
GSCO
Conviction Buy
Cigna upgraded to Conviction Buy from Buy at Goldman
Goldman analyst Matthew Borsch added Cigna (CI) to the Conviction Buy List saying saying shares are undervalued and sees upside potential in capital redeployment capacity. The analyst thinks news Federal antitrust regulators intend to block the Anthem (ANTM) merger will cause investors to focus on Cigna's strong standalone position driven by diversified business mix and ability to deploy at least $9B if it brought debt levels up to peers. Borsch lowered Cigna's price target to $165 from $170 on shares.
07/22/16
07/22/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Cigna (CI) upgraded to Conviction Buy from Buy at Goldman with analyst Matthew Borsch saying saying shares are undervalued and sees upside potential in capital redeployment capacity. 2. Exelon (EXC) upgraded to Buy from Hold at Deutsche Bank with analyst Jonathan Arnold saying the company is a "cheap play on regulated assets with catalysts." 3. UnitedHealth (UNH) upgraded to Buy from Hold at Argus with the firm saying it thinks that the company's decision to exit the Affordable Care Act exchanges next year will boost its Earnings Per Share in 2017, and it thinks that the outlook for the company's Optum businesses is "favorable." 4. Sherwin-Williams (SHW) upgraded to Buy from Outperform at CLSA with analyst Nils-Bertil Wallin citing valuation and sustainable long-term growth. 5. Viacom (VIAB) upgraded to Neutral from Underweight at Atlantic Equities. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$315.05

2.55 (0.82%)

10:21
11/18/17
11/18
10:21
11/18/17
10:21
Periodicals
Tesla new super car to cost $200,000, Recode says »

Alongside its new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 16

    Jan

GT

Goodyear Tire

$29.94

0.63 (2.15%)

10:17
11/18/17
11/18
10:17
11/18/17
10:17
Hot Stocks
Goodyear Tire, NASCAR extend relationship »

NASCAR and Goodyear Tire…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Jan

  • 16

    Jan

HMC

Honda

$32.62

0.02 (0.06%)

10:05
11/18/17
11/18
10:05
11/18/17
10:05
Periodicals
Honda recalls 900,000 minivans on tip forward seats, Reuters says »

Honda Motor is recalling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$88.43

-0.82 (-0.92%)

09:48
11/18/17
11/18
09:48
11/18/17
09:48
Periodicals
Activist investors Nelson Peltz still in P&G picture, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHGE

Baker Hughes

$30.91

0.76 (2.52%)

, GE

General Electric

$18.21

-0.04 (-0.22%)

09:39
11/18/17
11/18
09:39
11/18/17
09:39
Periodicals
Buy Baker Hughes, Barron's says »

While it is "not…

BHGE

Baker Hughes

$30.91

0.76 (2.52%)

GE

General Electric

$18.21

-0.04 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

CSCO

Cisco

$35.90

0.02 (0.06%)

09:19
11/18/17
11/18
09:19
11/18/17
09:19
Periodicals
More needed for Cisco to have 'groove back,' Barron's says »

While the Nasdaq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

IBM

IBM

$148.97

-0.15 (-0.10%)

09:10
11/18/17
11/18
09:10
11/18/17
09:10
Periodicals
IBM could be next to fetch higher valuation, Barron's says »

Investors are warming to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

GE

General Electric

$18.21

-0.04 (-0.22%)

09:05
11/18/17
11/18
09:05
11/18/17
09:05
Periodicals
Option play offer some help given GE dividend, depressed stock, Barron's says »

While wagering against…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

09:00
11/18/17
11/18
09:00
11/18/17
09:00
Periodicals
Risk remains after GE dividend cut, Barron's says »

While buying General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$88.72

0.71 (0.81%)

, T

AT&T

$34.51

-0.01 (-0.03%)

08:21
11/18/17
11/18
08:21
11/18/17
08:21
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

TWX

Time Warner

$88.72

0.71 (0.81%)

T

AT&T

$34.51

-0.01 (-0.03%)

NYT

New York Times

$17.65

0.05 (0.28%)

TEX

Terex

$44.82

0.8 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

TPIC

TPI Composites

$19.06

-0.97 (-4.84%)

07:25
11/18/17
11/18
07:25
11/18/17
07:25
Conference/Events
TPI Composites to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SYNA

Synaptics

$38.21

0.57 (1.51%)

04:55
11/18/17
11/18
04:55
11/18/17
04:55
Conference/Events
Synaptics management to meet with KeyBanc »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 06

    Dec

WGL

WGL Holdings

$84.32

-0.14 (-0.17%)

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Earnings
WGL Holdings reports Q4 adjusted EPS (17c), consensus (19c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

, LMOS

Lumos Networks

17:58
11/17/17
11/17
17:58
11/17/17
17:58
Hot Stocks
Tactile Systems to replace Lumos Networks in S&P 600 at open on 11/22 »

EQT Infrastructure…

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

, MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

17:56
11/17/17
11/17
17:56
11/17/17
17:56
Hot Stocks
Breaking Hot Stocks news story on Invesco Mortgage, MKS Instruments »

Invesco Mortgage to…

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

17:55
11/17/17
11/17
17:55
11/17/17
17:55
Hot Stocks
MKS Instruments to replace Brocade in S&P 400 at open on 11/22 »

S&P 500 constituent…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

UQM

UQM Technologies

$1.18

0.015 (1.29%)

17:24
11/17/17
11/17
17:24
11/17/17
17:24
Syndicate
Breaking Syndicate news story on UQM Technologies »

UQM Technologies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$238.02

-1.35 (-0.56%)

17:23
11/17/17
11/17
17:23
11/17/17
17:23
Periodicals
Goldman Sachs has $510M lawsuit dismissed, Reuters reports »

A $510M lawsuit that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICL

Vical

$1.94

-0.02 (-1.02%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Breaking Hot Stocks news story on Vical »

Biotechnology Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Ligand director sells 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CFO sells 6,559 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CEO sells 5,269 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBI

MBIA

$9.01

0.13 (1.46%)

17:15
11/17/17
11/17
17:15
11/17/17
17:15
Hot Stocks
Breaking Hot Stocks news story on MBIA »

Fine Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBCN

Rubicon

$8.07

0.1218 (1.53%)

17:03
11/17/17
11/17
17:03
11/17/17
17:03
Hot Stocks
Breaking Hot Stocks news story on Rubicon »

Bandera Partners reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.